Data from EMC - Curated by Toby Galbraith - Last updated 20 October 2016

Indication(s)

VIMOVO is indicated in adults for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient.

 

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Bedwetting

Essential screening, diagnosis and best strategies to manage bedwetting

Visit Bedwetting

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more

Visit Psoriasis

More information

Category Value
Orphan designation No
Type POM
Marketing authorisation holder AstraZeneca UK Ltd

Related Content